Defining Relationships Among Tests for Kidney Transplant Antibody-Mediated Rejection.

ABSTRACT:

Introduction

Effective therapies for kidney transplant antibody-mediated rejection (ABMR) will require accurate diagnoses plus assessment of ABMR activity, and the new tests that were used to show treatment effects in the clinical trial such as donor-derived cell-free DNA (dd-cfDNA) and molecular biopsy analysis (the Molecular Microscope Diagnostic System) could be useful.

Methods

Trifecta-Kidney (ClinicalTrials.gov #NCT04239703) studied 717 indication biopsies to define the relationships among the following 4 tests used for ABMR: (i) standard-of-care (SOC) local histologic biopsy ABMR diagnosis, (ii) MMDx ABMR diagnosis, (iii) dd-cfDNA, and (iv) donor-specific antibody (DSA).

Results

All 4 tests were correlated in a partial correlation network, with a hierarchy of in

SUBMITTER: Madill-Thomsen KS 

PROVIDER: S-EPMC12446986 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature